bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P1-02-08: 18F-fluoro-2-deoxy-glucose positron emission tomography/ computed tomography evaluation shows the utility for predicting postoperative outcomes on Luminal types breast cancer patients
Authors: Aogi Kenjiro , Sugawara Yoshifumi , Kiyoto Sachiko , Kadoya Takayuki , Shigematsu Hideo , Masumoto Norio , Okada Morihito 
Published: May 2015

Abstract
Background: Hormonal receptor-positive, i.e. Luminal types, breast cancer has better prognosis compared with other phenotypes, but predictive factors for postoperative outcomes have been in research besides hormonal receptor expressions. 18F-fluoro-2-deoxy-glucose positron emission tomography/ computed tomography (18F-FDG PET/CT) using maximum standardized uptake value (maxSUV) has been reported its utility as one of predictive markers for relapse-free survival (RFS) on breast cancer patients. In this retrospective study, the utility of 18F-FDG PET/CT was evaluated on predicting postoperative outcomes especially on Luminal types breast cancer patients. Methods: Three hundred forty four breast cancer patients with clinical Stage I-III who underwent preoperative 18F-FDG PET/CT were enrolled between January 2006 and December 2011 in two institutes. Patients classified into Luminal types, Luminal A(166 patients): Estrogen receptor(ER)(+) or Progesterone receptor (PR)(+), human epidermal growth factor receptor type2 (HER2) (-), nuclear grade(NG)1-2 or Luminal B(96 patients): ER(+) or PR(+), HER2(-), NG3, were evaluated in this study. Moreover, patients were also divided in two groups according to cut-off maxSUV on receiver operating characteristic (ROC) analysis (≤4.0 group vs &gt;4.0 group, AUC=0.830). Statistical analyses were performed using Student t test and log-rank test, and p values of less than 0.05 were considered to be statistically significant. Results: Significant correlations were shown between maxSUV and clinical T-factor, nuclear grade, vascular invasion and presence or absence of recurrence (p&lt;0.0001, p&lt;0.0001, p=0.0181, and p=0.0056, respectively). In uni- and multivariate analyses using Cox model for recurrence, only maxSUV was shown to be significant (p=0.021 and p=0.043, respectively). In RFS, the maxSUV≤4.0 group showed significantly better prognosis compared to that of the maxSUV &gt;4.0 group (p=0.003). Conclusion: 18F-FDG PET/CT using maxSUV was concluded to be useful for predicting postoperative prognosis on luminal types breast cancer patients.
Citation Format: Kenjiro Aogi, Yoshifumi Sugawara, Sachiko Kiyoto, Takayuki Kadoya, Hideo Shigematsu, Norio Masumoto, Morihito Okada. 18F-fluoro-2-deoxy-glucose positron emission tomography/ computed tomography evaluation shows the utility for predicting postoperative outcomes on Luminal types breast cancer patients [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-02-08.
Abstract P1-02-10: Contrast enhanced spectral mammography (CESM) is a new breast imaging contrast study: A review of indications, protocol, interpretation and pitfalls
Authors: Liao Lydia , Li Luna , Germaine Pauline , Tinney Elizabeth , Brill Kristin , Hendershott Karen 
Published: May 2015

Abstract
Purpose: This presentation is to discuss the indications, protocol, interpretation and pitfalls of CESM using illustrations of breast malignant and benign cases performed in our institution, after a brief literature review. CESM characteristics for both benign and malignant lesions are defined after comparison to other imaging studies and correlation to final tissue diagnosis.
Methods: 1000 CESM cases including 100 breast cancer and 200 benign lesions were retrospectively analyzed. These cases were performed in our institution from October 2012 to March 2014. GE Senographe Essential Full Field Digital System (SenoBright) was utilized for CESM studies. Both low and high energy images were obtained after intravenous 75-100cc Isovue 370 administration at flow rate of 1.5-2cc per second. Both low energy and subtracted images were reviewed on GE Centricity Imagecast on 5 megapigxel monitor. Abnormal CESM lesions underwent further evaluation and tissue sampling for a final diagnosis to determine the presence of breast cancer.
Results: CESM is one of the contrast studies. It provides both morphologic and functional information of breast lesions. The sensitivity of CESM for cancer detection was 93-100% per patient in contrast to 95-100% of breast MRI. There are morphological and enhancement features for both malignant and benign lesions on CESM. CESM could pick up lesions when regular digital mammography and ultrasound are negative. CESM is a part of diagnostic study on selected patients. It has a short duration exam time and results are easily accessible. Some CESM artifacts are unique and commonly occurred.
Conclusion: CESM is a new breast imaging contrast study. The sensitivity for breast cancer detection is comparable to breast MRI. With its easy accessibility and cost effectiveness, CESM may play an important role in breast cancer detection in conjunct with diagnostic mammography and breast ultrasound. Recognition of CESM artifacts helps to increase diagnostic accuracy.
Citation Format: Lydia Liao, Luna Li, Pauline Germaine, Elizabeth Tinney, Kristin Brill, Karen Hendershott. Contrast enhanced spectral mammography (CESM) is a new breast imaging contrast study: A review of indications, protocol, interpretation and pitfalls [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-02-10.
Abstract P1-03-05: Genetic variant in the OPG gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients
Authors: Lintermans Anneleen , Van Asten Kathleen , Laenen Annouschka , Van Brussel Thomas , Verhaeghe Johan , Vanderschueren Dirk , Lambrechts Diether , Neven Patrick 
Published: May 2015

Abstract
Background
Aromatase inhibitor (AI) therapy is associated with musculoskeletal toxicity, which adversely affects quality of life and therapy adherence. Our objective was to evaluate genetic predictors for endocrine therapy-related musculoskeletal pain in a prospective cohort study, which was previously published.
Patients & methods
254 early breast cancer patients starting AI (n=159) or tamoxifen therapy (n=95) were included in this genetic biomarker study. Musculoskeletal symptoms were assessed at baseline and at 3, 6 and 12 months thereafter. AI-induced musculoskeletal pain was defined as an increase in arthralgia or myalgia relative to baseline. Single nucleotide polymorphisms (SNP) in candidate genes involved in estrogen signaling or reported to have associations with AI-related musculoskeletal pain or estrogen levels were selected. Of the 40 selected SNPs, 7 failed genotyping and were excluded from further analysis.
Results
Twenty SNPs exhibited a minor allele frequency &lt;0.05 and were omitted from the final analysis. Overall, 13 SNPs in CYP19, CYP17, osteoprotegerin (OPG) and estrogen receptor 1 were included.
74% of AI-users reported new or worsened musculoskeletal pain compared to 33% of tamoxifen-treated patients. The OPG SNP rs2073618 was significantly associated with AI-induced musculoskeletal toxicity after correction for multiple testing (p=0.039). None of the other SNPs showed significant associations, both in AI and tamoxifen-treated patients.
Conclusion
The SNP rs2073618 in OPG predicts the risk of musculoskeletal symptoms with AI therapy, which has not been reported so far. Validation of this finding and further functional studies are needed.
Citation Format: Anneleen Lintermans, Kathleen Van Asten, Annouschka Laenen, Thomas Van Brussel, Johan Verhaeghe, Dirk Vanderschueren, Diether Lambrechts, Patrick Neven. Genetic variant in the OPG gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-03-05.
Abstract P1-06-04: Super-enhancer analysis defines breast cancer subtype and identifies tumor dependencies
Authors: Guenther Matthew G , Orlando David A , Eaton Matthew L , Collins Cindy A , Chen Mei Wei , Solanki Sneha , Loven Jakob , Fritz Christian C , Olson Eric R 
Published: May 2015

Abstract
Epigenomic modifications define gene regulatory features that control transcription and disease cell state. Recent studies of these regulatory features have identified large clusters of enhancers, termed super-enhancers, which define key cell identity and disease genes. Using ChIP-seq and RNA-seq analysis, we have discovered Super-enhancers in breast cancer cell line models and in primary tissue and have characterized their roles in establishing tumor cell state. We find that Super-enhancers recapitulate clinical subgroups in both breast cancer cell line models and in invasive ductal carcinoma. Super-enhancer-associated genes encode known and novel therapeutic targets including kinases, phosphatases, chromatin regulators and transmembrane proteins. Such genes include key drivers such as ERRB2 in HER2+ patient samples, ESR1 in estrogen receptor positive samples, and CCND1 in samples of luminal subtype. We describe the biological and disease relevance of Super-enhancer-associated genes in the context of tumor cell state and drug target discovery.
Citation Format: Matthew G Guenther, David A Orlando, Matthew L Eaton, Cindy A Collins, Mei Wei Chen, Sneha Solanki, Jakob Loven, Christian C Fritz, Eric R Olson. Super-enhancer analysis defines breast cancer subtype and identifies tumor dependencies [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-06-04.
Abstract P1-09-02: BMI and metabolic factors in long-term breast cancer survivors: Changes from diagnosis and comparison to non-breast cancer controls
Authors: Lohmann Ana Elisa , Ennis Marguerite , Goodwin Pamela J 
Published: May 2015

Abstract
Background: The metabolic syndrome is associated with poor breast cancer (BC) outcome. We evaluated changes from diagnosis in metabolic factors and BMI in long-term survivors and compared their status at long-term follow-up (LTFU) to that of age-matched women with no history of BC.
Methods: A total of 535 women with early breast cancer were enrolled between 1989 and 1996 and followed prospectively. From 2005 to 2007, those alive without distant recurrence were re-contacted to participate in a long-term followed-up study and 285 agreed. A control group of 167 age-matched women without cancer history was recruited from women presenting for screening mammograms. Mean changes in metabolic factors from diagnosis to long-term follow-up were assessed with paired t-tests. In spite of matching, controls were younger and had higher income than survivors and the comparison to controls was made using age-adjusted regression models. Variables were transformed to normality before statistical testing.
Results: With a median follow-up of 12.5 years, BC survivors gained on average 2.35 kg and BMI, waist and hip circumference, waist-hip ratio, glucose, insulin, HOMA, total cholesterol and its components (but not triglycerides) increased significantly. After age adjustment, waist circumference, glucose, HOMA and total triglycerides were significantly higher in BC survivors compared to controls
Comparison of LTFU BC survivors to non-cancer controls Unadjusted mean ± standard deviationUnadjusted mean ± standard deviation BC patientscontrolsP-value for age-adjusted differencewaist circumference (cm)85 ± 1281 ± 10.01Glucose (mmol/L)5.5 ± 1.05.2 ± 0.9.01Insulin (pmol/L)60.9 ± 50.547.1 ± 28.3.06HOMA2.25 ± 2.241.64 ± 1.24.03Triglycerides (mmol/L)1.28 ± 0.641.10 ± 0.57.01BMI (kg/m2)26.3 ± 4.925.4 ± 4.5.26
Despite exclusion of BC patients with diabetes at study entry, 24.9% of BC survivors self reported diabetes or pre-diabetes (1.99%/year) versus 12.6% in controls (OR 2.3, p= .0017).
Conclusion: The metabolic status of long-term BC survivors deteriorated over time and age-adjusted at LTFU were worse with respect to a number of factors compared to the control group.
Citation Format: Ana Elisa Lohmann, Marguerite Ennis, Pamela J Goodwin. BMI and metabolic factors in long-term breast cancer survivors: Changes from diagnosis and comparison to non-breast cancer controls [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-09-02.
Abstract P1-09-21: Metabolic syndrome is prevalent in women with newly diagnosed breast cancer
Authors: Wong Louise C , Behrendt Carolyn , Smith Robin , Mortimer Joanne E 
Published: May 2015

Abstract
Purpose: We estimate the prevalence of metabolic syndrome (MetSyn) among women with newly diagnosed breast cancer and explore potential risk factors.
Methods: From January 2012 to May 2014, women with newly diagnosed localized breast cancer were enrolled into a longitudinal survivorship study. At baseline, results of physical exam, use of concomitant medications, serum lipid profile and vitamin D were obtained from the medical record, while quality of life variables were measured via questionnaires in English. MetSyn was defined as at least 3 of 5 criteria: central obesity (BMI &gt;30 or waist &gt;=88 cm); triglycerides &gt;=150 mg/dL; HDL cholesterol &lt;50 mg/dL or cholesterol-lowering treatment; systolic &gt;=130 or diastolic &gt;=85 mm Hg blood pressure or treatment for hypertension; fasting glucose &gt;=100mg/dL or diagnosis of Type 2 diabetes. Risk factors for MetSyn (age, education, serum vitamin D, self-reported energy in past month) were evaluated using multivariate logistic regression.
Results: Subjects (n=154) were age 52.0 +10.1 years. Prevalence of MetSyn at baseline was 46.1(+4.0)%; for another 1.9(+1.1)% (n=3), MetSyn status was indeterminate due to lack of data on HDL and triglycerides. Among subjects with MetSyn (n=71), most had been diagnosed with hypertension (81.7%) and diabetes (61.4%). Without MetSyn (n=80), the latter conditions were much less prevalent (31.3% and 22.5%, respectively, both p&lt;0.0001). Adjusted for race and year of accrual, the likelihood of MetSyn at baseline was higher per year of age (Odds Ratio (O.R.) 1.05, 95% CI 1.01-1.10, p=0.015), lower per increasing educational attainment (from less than high school to high school/some college, to bachelor’s, to graduate degree: O.R. 0.58, 0.36-0.93, p=0.024), and higher per increasing "time in past month with a lot of energy" (from little/no time to most of the time, to all of the time: O.R. 2.30, 1.11-4.75, p=0.025). An inverse association with serum Vit D (p=0.14) did not reach statistical significance.
Conclusions: Metabolic syndrome is present in nearly half of women newly diagnosed with breast cancer and is associated with age, less education, and more energy in past month.
Citation Format: Louise C Wong, Carolyn Behrendt, Robin Smith, Joanne E Mortimer. Metabolic syndrome is prevalent in women with newly diagnosed breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-09-21.
Abstract P1-09-23: Symptoms, desire for help, and quality of life among recent breast cancer survivors
Authors: Palmer Steven C , Panzer SarahLena L , Glanz Karen , Schapira Marilyn M , DeMichele Angela M , Jacobs Linda A 
Published: May 2015

Abstract
Introduction:
Advances in detection and treatment have led to improved survival among breast cancer (BC) patients and 89% can expect &gt;5 year survival. Progress comes at a cost, however, and patients experience lasting effects from disease and treatment. It is not clear how these effects impact quality of life (QoL) achieved by BC survivors. We examined relationships between symptoms, desire for help, and QoL among recent BC survivors.
Method:
Eligibility included non-metastatic BC treated &lt; 1 year prior and attendance at a survivorship clinic. QoL was assessed with the SF-12. 19 common symptoms were assessed on a 0-5 bother scale. Participants reported desire for help item for each symptom rated &gt; 1.
Results:
171 primarily white (73%), middle aged (M=54.9 yrs), and Stage I (58%) BC survivors were recruited. Both Physical (M=48.1) and Mental (M=53.8) QoL were similar to national norms. Survivors reported an average of 12 symptoms, most commonly Fatigue (90%), Insomnia (75%), Hot Flashes (73%), and Joint Pain (70%). Most bothersome symptoms included Joint Pain (M=2.9), Decreased Sexual Drive (M=2.8), Hot Flashes (M=2.8), and Vaginal Dryness (M=2.7). Participants desired help with few symptoms (M=2.3), primarily Weight Gain (50%), Joint Pain (45%), and Numbness in Hands/Feet (44%). Both Physical and Mental QoL were negatively associated with number of symptoms experienced (r = -.46 and -.41, respectively) and number of symptoms for which help was desired (r = -.16 and -.41, respectively).
Conclusion:
Symptoms are common among recent breast cancer survivors and negatively impact Physical and Mental QoL. Desire for help is less common, though similarly associated with impairment in QoL. Assessing QoL in isolation from symptom burden may miss important areas for which remediation is possible and could result in improved QoL. Patient education regarding the potential for and value of symptom reduction may be needed in BC survivors.
Citation Format: Steven C Palmer, SarahLena L Panzer, Karen Glanz, Marilyn M Schapira, Angela M DeMichele, Linda A Jacobs. Symptoms, desire for help, and quality of life among recent breast cancer survivors [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-09-23.
Abstract P1-09-28: What is a healthful diet? – Cancer survivors' interpretations of their own dietary recall data
Authors: Klassen Ann C , Smith Katherine C , Brosbe Michelle , Coa Kisha , Hannum Susan , Caulfield Laura 
Published: May 2015

Abstract
Background
The number of long-term cancer survivors will continue to grow, and developing strategies for tertiary prevention of recurrence, cancer-related comorbidities, and general chronic disease-related health burden is critical. Nutrition and energy balance are increasingly recognized to play important roles in both decreasing recurrence risk, and improving health and well-being throughout survivorship. To inform strategies for nutrition education and behavior change for cancer survivors, we used a mixed methods approach to explore concepts about healthful diet and eating patterns among long-term cancer survivors.
Methods
We collected three ASA-24 dietary recalls from 53 breast, prostate and non-Hodgkins lymphoma survivors. Utilizing qualitative interviews, we provided participants with feedback on how their eating patterns compared to dietary guidelines, and asked respondents to reflect upon their diet and dietary changes.
Results
Like most American adults, respondents were not eating in accordance with many dietary recommendations. In terms of adequate intake of recommended nutrients, 68% met fruit and vegetable guidelines, but only 15% reported adequate intake of fiber. In terms of following recommendations for limits on intake, 89% reported diets that met guidelines for limiting alcohol intake, but only 55% met limits for cholesterol, 40% for saturated fat, 19% for caloric intake, and only 2% limited their sodium intake to within recommended levels. Respondents were often surprised by their own dietary patterns, and had differing conceptualizations of a "healthful" diet.
Conclusions
Cancer survivorship may provide motivation for dietary change, but survivors need nutrition education to identify specific strategies for dietary improvement.
Citation Format: Ann C Klassen, Katherine C Smith, Michelle Brosbe, Kisha Coa, Susan Hannum, Laura Caulfield. What is a healthful diet? – Cancer survivors' interpretations of their own dietary recall data [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-09-28.
Abstract P1-10-05: A cost utility analysis from a Chinese health care perspective of Nab-paclitaxel or docetaxel, both as alternatives to solvent-based paclitaxel in metastatic breast cancer (MBC)
Authors: Dranitsaris George , Yu Bo , King Jennifer , Zhang Adams , Kaura Satyn , Qing Zhai 
Published: May 2015

Abstract
Background: Paclitaxel and docetaxel are commonly used for the treatment of MBC in China. However, one important drawback, particularly with docetaxel, is the potential for dose-limiting toxicity. To improve the side effect profile and efficacy of paclitaxel, an albumin-bound formulation (nab-paclitaxel) is currently available in China (Abraxane®). To provide health economic data for China, a cost utility analysis comparing nab-paclitaxel to docetaxel, both as alternatives to paclitaxel was conducted.
Methods: Clinical data was obtained from a meta analysis of randomized trials comparing either nab-paclitaxel (260 mg/m2 q3wk) or branded docetaxel (100 mg/m2 q3wk) to solvent-based branded paclitaxel (175 mg/m2 q3wk). Health care resource use for the delivery of chemotherapy and the management of grade 3/4 toxicity was collected from a time and motion study in three Chinese cancer centers, from a survey of clinicians and from the oncology literature. Using the Time Trade-off technique, treatment preferences and utility estimates were obtained from interviewing 28 cancer patients from two centres in China. All costs were reported in 2014 $U.S.
Results: Nab-paclitaxel had the most favourable safety profile characterized with the lowest incidence of grade 3/4 neutropenia, febrile neutropenia, anemia, emesis and stomatitis. This translated to lower costs for managing the grade 3/4 side effects of nab-paclitaxel relative to both docetaxel and paclitaxel ($21 vs. $166 vs. $81) In the preference assessment, 22 of 28 (78.6%) patients selected nab-paclitaxel as their preferred agent. As an alternative to paclitaxel, the incremental cost per quality adjusted life year (QALY) gained was determined to be more favourable with nab-paclitaxel than docetaxel ($57,900 vs. $130,600).
Conclusions: Nab-paclitaxel is an economically attractive alternative to both paclitaxel and docetaxel in MBC patients, providing a substantially lower cost per QALY. Additionally in the patient preference survey, the majority of patients surveyed selected nab-paclitaxel as their preferred agent.
Citation Format: George Dranitsaris, Bo Yu, Jennifer King, Adams Zhang, Satyn Kaura, Zhai Qing. A cost utility analysis from a Chinese health care perspective of Nab-paclitaxel or docetaxel, both as alternatives to solvent-based paclitaxel in metastatic breast cancer (MBC) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-10-05.